Contamination Control Strategy (CCS) Implementation in Aseptic Biologics Manufacturing
Case Study: Contamination Control Strategy (CCS) Implementation in Aseptic Biologics Manufacturing
12.03.2026
Case Study
Case Study Overview
Contamination Control Strategy (CCS) is now a cornerstone of EU GMP Annex 1 compliance. For biologics manufacturers, gaps in sterility assurance or Environmental Monitoring can lead to failed inspections, product risks, and reputational damage. This case study shows how GMP Bridge helped a mid-sized manufacturer in the DACH region design and implement a compliant CCS, strengthen oversight, and achieve inspection readiness ahead of schedule.
The Challenge
A mid-sized biologics manufacturer in the DACH region needed to rapidly align with the revised EU GMP Annex 1 requirements. Sterility assurance processes were fragmented, Environmental Monitoring lacked risk-based design, and an upcoming health authority inspection was approaching with identified compliance gaps. Without a structured Contamination Control Strategy, the site risked critical findings and delays to market supply.
Solution Delivered
GMP Bridge supported the organization in implementing a comprehensive Contamination Control Strategy aligned with EU GMP Annex 1 to strengthen sterility assurance and prepare the site for regulatory inspections.
Impact and Results
The CCS implementation significantly strengthened sterility assurance, improved contamination control governance, and prepared the organization for upcoming regulatory inspections.
Fully Implemented CCS Framework
A comprehensive Contamination Control Strategy was successfully implemented and made auditable ahead of the scheduled inspection.
Inspection Readiness Achieved
The site achieved inspection readiness, restoring regulatory confidence in the sterility assurance framework.
Strengthened Sterility Assurance
Contamination control processes across aseptic manufacturing operations were reinforced to ensure robust sterility assurance.
Risk-Based Mitigation of Contamination Risks
Critical contamination risks were systematically mitigated through structured risk assessments and targeted action plans.
Enhanced Ownership and Governance
A dedicated Quality Oversight program strengthened accountability and ownership of contamination control activities across teams.
Company Details
- Region: DACH
- Company: Mid-sized biologics manufacturer
- Products: Monoclonal antibodies, sterile drug products
Ready to talk the specifics?
So Are we - Get in Touch
- (+49) 174 957 5861
- contact@gmpbridge.com